Reprieve Cardiovascular
Reprieve Cardiovascular raises $61M Series B at $300M valuation
Quick Facts
Reprieve Cardiovascular: Series B Funding Round
Reprieve Cardiovascular has successfully raised $61M in Series B funding, reaching a valuation of $300M.
Company Overview
Developer of therapy for acute decompensated heart failure
Funding Details
The Series B round was led by New Enterprise Associates, with participation from Sofinnova Partners.
Company Information
- Headquarters: Milford, MA
- Founded: 2018
- Employees: 70+
- Category: HealthTech
Investment
Reprieve Cardiovascular plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- New Enterprise Associates: Verified investor in Series B
- Sofinnova Partners: Verified investor in Series B
Key Investors
About the Author
Related Company Reports
Abridge Raises $150M Series C to Transform HealthTech
Abridge has secured $150M Series C in funding to accelerate growth and innovation in the healthtech sector. Medical AI scribe platform automatically documenting patient-provider conversations and generating clinical notes...
Innovaccer Raises $275M Series F to Transform HealthTech
Innovaccer has secured $275M Series F in funding to accelerate growth and innovation in the healthtech sector. Healthcare data platform unifying patient data and providing analytics for value-based care and population health manage...
Truveta Raises $95M Series B to Transform HealthTech
Truveta has secured $95M Series B in funding to accelerate growth and innovation in the healthtech sector. Healthcare data platform aggregating de-identified patient records to accelerate medical research and drug development...
